Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
T cells that accompany allogeneic hematopoietic grafts for treating leukemia enhance engraftment and mediate the graft-versus-leukemia effect. Unfortunately, alloreactive T cells also cause graft-versus-host disease (GVHD). T cell depletion prevents GVHD but increases the risk of graft rejection and leukemic relapse. In human transplants, we show that donor-versus-recipient natural killer (NK)-cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD. In mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GVHD. NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NK cells, which act as important immune cells, are widely used for transplantation [82,83].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [82]
Citations
Cites
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Lanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., & Emerson, S. G. (1999) · Science · doi:10.1126/science.285.5426.412 · Cited by 1,186
Self-citationAversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391702 · Cited by 1,168
Self-citationRole of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999) · Blood · doi:10.1182/blood.v94.1.333.413a31_333_339 · Cited by 994
Self-citationHematopoietic Cell Transplantation
Forman, S. J., & Nakamura, R. (2015) · Blackwell Science Ltd eBooks · Cited by 659
Aversa, F., Tabilio, A., Terenzi, A., Velardi, A., Falzetti, F., Giannoni, C., Iacucci, R., Zei, T., Martelli, M., & Gambelunghe, C. (1994) · Blood · doi:10.1182/blood.v84.11.3948.bloodjournal84113948 · Cited by 576
Self-citationColonna, M., Borsellino, G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.12000 · Cited by 460
Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
Bachar-Lustig, E., Rachamim, N., Li, H.-W., Lan, F., & Reisner, Y. (1995) · Nature Medicine · doi:10.1038/nm1295-1268 · Cited by 322
Generation of Allospecific Natural Killer Cells by Stimulation Across a Polymorphism of HLA-C
Colonna, M., Brooks, E. G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Science · doi:10.1126/science.8493555 · Cited by 234
Research works printed but not linked: 3
- Valiante N. M., Parham P., Biol. Blood Marrow Transplant. 3, 229 (1997).
- A supplementary table and experimental procedures are available on Science Online at www.sciencemag.org/cgi/content/full/295/5562/2097/DC1.
- We thank A. Santucci for statistical analyses L. Romani for critical review of the manuscript and G. Boyd for her essential role in manuscript editing. Supported by grants from the Italian Association for Cancer Research the Italian Ministry of Research and the Italian Ministry of Health and by a translational research grant from the Leukemia and Lymphoma Society. W.D.S. is supported by NIH grant number HL03979.
Cited by
Items 701–800 of 1,002
Natural killer cell immunotherapy for cancer: a new hope
Srivastava, S., Lundqvist, A., & Childs, R. W. (2008) · Cytotherapy · doi:10.1080/14653240802648181 · Cited by 89
Dissecting graft‐versus‐leukemia from graft‐versus‐host‐disease using novel strategies
Warren, E. H., & Deeg, H. J. (2013) · Tissue Antigens · doi:10.1111/tan.12090 · Cited by 77
“Pioneering studies by the transplant group in Perugia suggested that eradication of leukemic cells in recipients of extensively T-depleted grafts from haploidentical or multiple HLA-mismatched donors was in large part due to alloreactive donor-derived NK cells (6).”
BackgroundPlatelet-Derived Ectosomes Reduce NK Cell Function
Sadallah, S., Schmied, L., Eken, C., Charoudeh, H. N., Amicarella, F., & Schifferli, J. A. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502658 · Cited by 77
Fry, T. J., & Mackall, C. L. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704848 · Cited by 82
de Santis, D., Bishara, A., Witt, C., Nagler, A., Brautbar, C., Slavin, S., & Christiansen, F. (2005) · Tissue Antigens · doi:10.1111/j.1399-0039.2005.00396.x · Cited by 82
The immunogenetics of neurological disease
Misra, M. K., Damotte, V., & Hollenbach, J. A. (2018) · Immunology · doi:10.1111/imm.12869 · Cited by 74
New Approaches to Graft Engineering for Haploidentical Bone Marrow Transplantation
Handgretinger, R. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.09.007 · Cited by 80
“Designed” grafts for HLA-haploidentical stem cell transplantation
Martelli, M. F., Ianni, M. D., Ruggeri, L., Pierini, A., Falzetti, F., Carotti, A., Terenzi, A., Reisner, Y., Aversa, F., Falini, B., et al. (2013) · Blood · doi:10.1182/blood-2013-10-531764 · Cited by 80
Self-citationVitale, M., Cantoni, C., Chiesa, M. D., Ferlazzo, G., Carlomagno, S., Pende, D., Falco, M., Pessino, A., Muccio, L., Maria, A. D., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01415 · Cited by 79
“-host disease in bone marrow transplantation (40) and graft rejection in solid organ transplantation (173, 174).”
BackgroundInducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells
Wang, X., Jasinski, D. L., Medina, J. L., Spencer, D. M., Foster, A. E., & Bayle, J. H. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001510 · Cited by 77
“Moreover, because NK cells lack a TCR, they have greatly reduced capacity to elicit GVHD, raising the potential to develop standardized, donor-derived, off-the-shelf therapies.(3,10,11) In fact, very promising clinical results have now been reported for the targeting of B-cell neoplasms with allogeneic secondgeneratio…”
BackgroundRecombinant structures expand and contract inter and intragenic diversification at the KIR locus
Pyo, C., Wang, R., Vu, Q., Cereb, N., Yang, S. Y., Duh, F.-M. C., Wolinsky, S. M., Martin, M. P., Carrington, M. N., & Geraghty, D. E. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-89 · Cited by 79
“KIR was implicated in hematopoetic cell transplantation not long after the delineation of KIR genetic structures [16] and more recently specific KIR haplotype substructures were associated with improved outcomes of unrelated transplants for acute myelogenous leukemia [17].”
BackgroundLocatelli, F., Pende, D., Maccario, R., Mingari, M. C., Moretta, A., & Moretta, L. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.04.009 · Cited by 80
Saudemont, A., Garçon, F., Yadi, H., Roche-Molina, M., Kim, N., Segonds-Pichon, A., Martín-Fontecha, A., Okkenhaug, K., & Colucci, F. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808594106 · Cited by 74
“For example, p110 inhibitors may be effective to treat Acute Myeloid Leukemia (47, 48), a malignancy that is targeted by allogeneic donor NK cells upon bone marrow transplantation (49).”
BackgroundRousseau, R. F., Biagi, E., Dutour, A., Yvon, E. S., Brown, M. P., Lin, T. F., Mei, Z., Grilley, B., Popek, E. J., Heslop, H. E., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1259 · Cited by 75
“While leukemic cells are susceptible to cytotoxic effector activities both in vitro and in vivo, it is yet not clear which components of the immune and innate responses are most critical for the effective destruction of the host leukemia in vivo.(44-46) Experimental results confirm the pivotal role of CD4 T cells in p…”
BackgroundRisk assessment in haematopoietic stem cell transplantation: Histocompatibility
Petersdorf, E. W. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2006.09.001 · Cited by 74
Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect
Ortí, G., Barba, P., Fox, M. L., Salamero, O., Bosch, F., & Valcárcel, D. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.12.004 · Cited by 74
Strategies of Natural Killer Cell Recognition and Signaling
Stewart, C. A., Vivier, É., & Colonna, M. (2005) · Current topics in microbiology and immunology · doi:10.1007/3-540-27743-9_1 · Cited by 84
“It is also known that NK KIR-HLA interactions can be exploited during certain bone marrow transplantation procedures where incompatibility decreases the likelihood of graft-versus-host disease and leukemia relapse (Ruggeri et al. 2002).”
BackgroundRevving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies
Pittari, G., Filippini, P., Gentilcore, G., Grivel, J., & Rutella, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00230 · Cited by 81
“, KIR-ligand mismatch in the GVH direction) (23, 24).”
BackgroundGenetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo
Sola, C., André, P., Lemmers, C., Fuséri, N., Bonnafous, C., Bléry, M., Wagtmann, N. R., Romagné, F., Vivier, É., & Ugolini, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901653106 · Cited by 73
“In particular, retrospective studies of KIR-HLA mismatched stem cell transplantation in acute myeloid leukemia patients showed that the lack of KIR engagement on donor NK cells by patient MHC class I molecules was associated with a significant reduced risk for leukemia relapse (20, 21).”
BackgroundCytokine-induced memory-like natural killer cells for cancer immunotherapy
Tarannum, M., & Romee, R. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02655-5 · Cited by 77
“The fine tuning of the NK cell function by activating receptors binding cognate ligands on the tumor cells and lack of inhibition by inhibitory receptors allows NK cells to recognize and target allogeneic tumor cells [23], and this Fig.”
BackgroundMaddineni, S., Silberstein, J. L., & Sunwoo, J. B. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004693 · Cited by 75
Dufva, O., Gandolfi, S., Huuhtanen, J., Dashevsky, O., Duàn, H., Saeed, K., Klievink, J., Nygren, P. J., Bouhlal, J., Lahtela, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.008 · Cited by 87
Natural killer cell-based immunotherapeutic strategies
Klingemann, H.-G. (2005) · Cytotherapy · doi:10.1016/s1465-3249(05)70785-4 · Cited by 73
Critical role of host γδ T cells in experimental acute graft-versus-host disease
Maeda, Y., Reddy, P. R., Lowler, K. P., Liu, C., Bishop, D. K., & Ferrara, J. L. M. (2005) · Blood · doi:10.1182/blood-2004-10-4087 · Cited by 75
Renal Transplant Immunosuppression Impairs Natural Killer Cell Function In Vitro and In Vivo
Morteau, O., Blundell, S., Chakera, A., Bennett, S. C., Christou, C. M., Mason, P. D., Cornall, R. J., & O’Callaghan, C. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013294 · Cited by 73
“It has been reported that human NK cells can mediate rejection of both allogeneic bone marrow and xenogeneic solid organ grafts [15,16,17,18,19].”
BackgroundAllogeneic stem cell transplantation for chronic myeloid leukemia
Barrett, J. A. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)70043-2 · Cited by 73
Lanuza, P. M., Pesini, C., Arias, M. A., Calvo, C., Ramírez-Labrada, A., & Pardo, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03010 · Cited by 75
“Specifically, those patients that received a transplant from an haploidential donor and, thus, presented NK cell alloreactivity, prevented leukemia relapse (53).”
BackgroundIn Vivo Role of Flt3 Ligand and Dendritic Cells in NK Cell Homeostasis
Guimond, M., Freud, A. G., Mao, H. C., Yu, J., Blaser, B. W., Leong, J. W., VanDeusen, J. B., Dorrance, A. M., Zhang, J., Mackall, C. L., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0900685 · Cited by 72
“Exogenous FL administration may provide the best way to selectively expand and activate NK cells when considering this therapy that benefits leukemia patients (41).”
BackgroundBoyiadzis, M. M., Memon, S. A., Carson, J. M., Allen, K., Szczepański, M. J., Vance, B. A., Dean, R. M., Bishop, M., Gress, R. E., & Hakim, F. T. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.12.490 · Cited by 72
Zingoni, A., Ardolino, M., Santoni, A., & Cerboni, C. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00408 · Cited by 81
“Previous studies demonstrated that donor NK cells are able to suppress the development of GVHD through the killing of host antigen-presenting cells which are essential for donor T cell activation (Ruggeri et al., 2002).”
George, B. M., Kao, K. S., Kwon, H.-S., Velasco, B. J., Poyser, J., Chen, A. C., Le, A., Chhabra, A., Burnett, C. E., Cajuste, D., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.05.018 · Cited by 75
Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma
Illhardt, T., Toporski, J., Feuchtinger, T. F., Turkiewicz, D., Teltschik, H., Ebinger, M., Schwarze, C.-P., Holzer, U., Lode, H. N., Albert, M. H., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.12.805 · Cited by 75
Kaur, K., Kozłowska, A. K., Topchyan, P., Ko, M.-W., Ohanian, N., Chiang, J., Cook, J., Maung, P. O., Park, S., Cacalano, N. A., et al. (2019) · Cancers · doi:10.3390/cancers12010063 · Cited by 71
“The use of allogeneic NK cells in hematologic malignancies following HLA‐haploidentical HSCT in clinical trials has previously been reported [38,39].”
InfluentialInnate Immune Recognition and Suppression of Tumors
Hayakawa, Y., & Smyth, M. J. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)95008-8 · Cited by 83
A Distinct Subpopulation of Human NK Cells Restricts B Cell Transformation by EBV
Lünemann, A., Vanoaica, L. D., Azzi, T., Nadal, D., & Münz, C. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301046 · Cited by 85
Haas, P., Loiseau, P., Tamouza, R., Cayuela, J., Moins‐Teisserenc, H., Busson, M., Henry, G., Falk, C. S., Charron, D. J., Socié, G., et al. (2010) · Blood · doi:10.1182/blood-2010-02-269381 · Cited by 77
Feasibility and Outcome of Reduced‐Intensity Conditioning in Haploidentical Transplantation
Handgretinger, R., Chen, X., Pfeiffer, M. M., Mueller, I., Feuchtinger, T. F., Hale, G. A., & Lang, P. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1392.022 · Cited by 71
Heining, C., Spyridonidis, A., Bernhardt, E., Schulte‐Mönting, J., Behringer, D. M., Grüllich, C., Jakob, A., Bertz, H., & Finke, J. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705648 · Cited by 71
“In this context, recently published studies emphasized the role of natural killer (NK) cells in a mismatch transplant settin”
BackgroundPérez‐Martínez, A., Leung, W. H., Muñoz, E., Iyengar, R. V., Ramírez, M. R., Vicario, J. L., Lassaletta, Á., Sevilla, J., González‐Vicent, M., Madero, L., et al. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.21955 · Cited by 71
“as demonstrated in adult AML by the Perugia group [18,19] and in pediatric AML and ALL by the Memphis group [20].”
ResultNatural Killer Cells: Angels and Devils for Immunotherapy
Martín-Antonio, B., Suñé, G., Pérez-Amill, L., Castellà, M., & Urbano-Ispizúa, Á. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091868 · Cited by 80
Mastaglio, S., Wong, E. Y. L., Perera, T., Ripley, J., Blombery, P. A., Smyth, M. J., Koldej, R. M., & Ritchie, D. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017015230 · Cited by 82
Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation
Schmidt, L., Eskiocak, B., Kohn, R., Dang, C., Joshi, N. S., DuPage, M. J. P., Lee, D.-Y., & Jacks, T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904253116 · Cited by 79
“In genetically engineered lung cancer in mice, stimulation of natural killer cells in established disease led to enhanced adaptive immune responses, presenting a strategy for improving the efficacy of cancer immunotherapy. myeloid leukemia patients (18).”
Shared biology of GVHD and GVT effects: Potential methods of separation
Fowler, D. H. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.07.001 · Cited by 82
Zhang, J., Sun, R., Wei, H., Zhang, J., & Tian, Z. (2004) · PubMed · Cited by 71
Lymphoid Regeneration from Gene-Corrected SCID-X1 Subject-Derived iPSCs
Menon, T., Firth, A. L., Scripture-Adams, D. D., Galić, Z., Qualls, S. J., Gilmore, W. B., Ke, E., Singer, O., Anderson, L., Bornzin, A. R., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.02.005 · Cited by 75
Littera, R., Piredda, G., Argiolas, D., Lai, S., Congeddu, E., Ragatzu, P., Melis, M., Carta, E., Michittu, M. B., Valentini, D., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180831 · Cited by 71
The Role of Natural Killer Cells in the Immune Response in Kidney Transplantation
Pontrelli, P., Rascio, F., Castellano, G., Grandaliano, G., Gesualdo, L., & Stallone, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01454 · Cited by 73
“Inhibitory KIRs expressed by NK cells of solid organ transplant recipients with donor mismatched for HLA KIR ligands may not recognize HLA class I molecules of donor and may dramatically induce NK cell alloreactivity against the graft (68, 69).”
BackgroundHejazi, M., Manser, A. R., Frobel, J., Kündgen, A., Zhao, X., Schönberg, K., Germing, U., Haas, R., Gattermann, N., & Uhrberg, M. (2015) · Haematologica · doi:10.3324/haematol.2014.118679 · Cited by 75
“In this regard, NK cells were previously implicated in relapse control following allogeneic hematopoietic stem cell transplantation for myeloid leukemia.(21) Moreover, recent studies have associated certain KIR gene linkage groups with decreased relapse and improved outcome in patients undergoing hematopoietic stem ce…”
BackgroundERAP1 Regulates Natural Killer Cell Function by Controlling the Engagement of Inhibitory Receptors
Cifaldi, L., Romania, P., Falco, M., Lorenzi, S., Meazza, R., Petrini, S., Andreani, M., Pende, D., Locatelli, F., & Fruci, D. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1643 · Cited by 78
“The success of this approach is explained by the transplantation of donor-derived alloreactive NK cells, which persist in patients after haploidentical HSCT for years, contributing to the eradication of malignant cells (32).”
BackgroundInfluentialDecot, V., Voillard, L., Latger‐Cannard, V., Aïssi-Rothé, L., Perrier, P., Stoltz, J., & Bensoussan, D. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.02.006 · Cited by 78
“During allogeneic hematopoietic stem cell transplantation, NK cells have been implicated in the suppression of GvHD, the promotion of bone marrow engraftment, and mediation of a GvL effect [7].”
BackgroundKiller Immunoglobulin-like Receptors and Tumor Immunity
Benson, D. M., & Caligiuri, M. A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0219 · Cited by 77
“Patients with acute leukemia first received an extensive preparative, conditioning regimen followed by an infusion of a high dose of CD34þ hematopoietic stem cells without graft-versus-host disease prophylaxis (28, 29).”
MethodVoskens, C., Watanabe, R., Rollins, S., Campana, D., Hasumi, K., & Mann, D. L. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-134 · Cited by 73
“Importantly, clinical effects are demonstrated when inhibitory effects are bypassed by utilizing haplo-identical NK cells and best results are achieved when, in addition, KIR-ligand mismatched NK cells are selected [8,9].”
Pegram, H. J., Jackson, J. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.3449 · Cited by 75
“Recent results have demonstrated that treatment of acute myeloid leukemia patients with alloreactive NK cells could substantially increase their survival without associated graftvs-host effects (14).”
BackgroundResultLundqvist, A., Berg, M., Smith, A. L., & Childs, R. W. (2011) · Journal of Cancer · doi:10.7150/jca.2.383 · Cited by 80
Ewen, E., Pahl, J. H. W., Miller, M., Watzl, C., & Cerwenka, A. (2017) · European Journal of Immunology · doi:10.1002/eji.201747128 · Cited by 70
Complex role of NK cells in regulation of oncolytic virus–bortezomib therapy
Kim, Y., Yoo, J. Y., Lee, T. J., Liu, J. N., Yu, J., Caligiuri, M. A., Kaur, B., & Friedman, A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715295115 · Cited by 70
Pulsipher, M. A., Bader, P., Klingebiel, T. E., & Cooper, L. J. N. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.11.009 · Cited by 76
“But for adult patients with B-ALL, relapse-free survival after T cell–depleted HLA-mismatched (HLA-haploidentical) hematopoietic stem cell transplantation (HSCT) typically has not been improved by KIR-ligand mismatches between donor and recipient [57].”
BackgroundModulation of innate immunity in the tumor microenvironment
González-Gugel, E., Saxena, M., & Bhardwaj, N. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1859-9 · Cited by 73
“In addition, there is evidence of early benefit from NK cell adoptive cell therapies (ACT) in leukemia and melanoma patients [24, 25] The role of peripheral blood NK cells has been described mainly during the course of acute and chronic infections where NK cells undergo transient or persistent modulation of activating…”
iPSC-Derived Natural Killer Cells for Cancer Immunotherapy
Karagiannis, P., & Kim, S.-I. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0078 · Cited by 67
“ic NK cells are commonly used in ACT, expanding the number of available donors, a significant plus when compared with T cell immunotherapies (Ruggeri et al., 2002).”
BackgroundKiller cell immunoglobulin-like receptor (KIR) gene content variation in the HGDP-CEPH populations
Hollenbach, J. A., Nocedal, I., Ladner, M. B., Single, R. M., & Trachtenberg, E. (2012) · Immunogenetics · doi:10.1007/s00251-012-0629-x · Cited by 71
“2004) as well as being important in solid organ and hematopoietic stem cell transplant (Cooley et al. 2009, 2010; Ruggeri et al. 2002; Kunert et al. 2007) and pregnancy (Moffett and Hiby 2007; Moffett-King 2002; Lanier 1999).”
BackgroundOverview of the Killer Cell Immunoglobulin-Like Receptor System
Rajalingam, R. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-842-9_23 · Cited by 74
Boieri, M., Ulvmoen, A., Sudworth, A., Lendrem, C., Collin, M. P., Dickinson, A. M., Kveberg, L., & Inngjerdingen, M. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1274478 · Cited by 79
“Immunotherapy with different NK-cell-based strategies is showing promise in the clinic, in particular against AML.6,7,32 Similar treatment of ALL has been less successful, likely due to their higher resistance toward NK cells.8 T-ALL blasts are particularly resistant to NK cells, but studies investigating NK cells in…”
BackgroundInfluentialRestoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
Pittari, G., Vago, L., Festuccia, M. B., Bonini, C., Mudawi, D., Giaccone, L., & Bruno, B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01444 · Cited by 76
“However, despite their tremendous efficacy, CAR-T cells have also raised concerns on their short-and long-term toxicities, in particular the development of life-threatening cytokine release syndrome and the risks of prolonged aplasia of the healthy counterparts of the target tumor—“off tumor/on target toxicity”—and in…”
JUNG, I. H., KIM, D. H., YOO, D. K., BAEK, S. Y., JEONG, S. H., JUNG, D. E., PARK, S. W., & CHUNG, Y.-Y. (2018) · In Vivo · doi:10.21873/invivo.11307 · Cited by 70
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy
Maia, A., Tarannum, M., Lérias, J. R., Piccinelli, S., Borrego, L. M., Maeurer, M. J., Romee, R., & Castillo-Martín, M. (2024) · Cells · doi:10.3390/cells13050451 · Cited by 74
“This review aims to elucidate several strategies used to improve NK cell proliferation and antitumor function, either through expansion methodologies, cytokine stimulation, or genetic modifications.”
MethodEissens, D., van der Meer, A., van Cranenbroek, B., Preijers, F. W. M. B., & Joosten, I. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03242.x · Cited by 74
Liu, H., Yang, B. Y., Sun, T., Lin, L., Hu, Y., Deng, M., Yang, J., Liu, T., Li, J., Sun, S., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3548 · Cited by 73
The role of natural killer cells in immunity against multiple myeloma
Godfrey, J. K., & Benson, D. M. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.676175 · Cited by 79
Bari, R., Rujkijyanont, P., Sullivan, E., Kang, G., Turner, V., Gan, K., & Leung, W. H. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.4007 · Cited by 68
“KIR-mediated alloreactivity was first predicted based on the donor HLA ligand repertoire.(5,13) KIR genotyping was then used to directly measure the donor gene content.”
BackgroundMethodLim, S. A., Kim, T.-J., Lee, J. E., Sonn, C. H., Kim, K., Kim, J., Choi, J. G., Choi, I.-K., Yun, C., Kim, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2893 · Cited by 68
“Clinical evidence of antitumor responses attributable to NK cells can be found in the setting of haploidentical allogeneic stem cell transplantation for leukemia where improved survival following transplant was noted among patients receiving donor NK cells which were KIR-ligand mismatched (4, 5).”
InfluentialLymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT
Bühlmann, L., Buser, A. S., Cantoni, N., Gerull, S., Tichelli, A., Gratwohl, A. A., & Stern, M. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.306 · Cited by 68
Ge, L., Ye, F., Mao, X., Chen, J., Sun, A., Zhu, X., Qiu, H., Jin, Z., Miao, M., Fu, C., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.03.030 · Cited by 68
“killing by natural killer cells [22].”
Pira, G. L., Malaspina, D. C., Girolami, E., Biagini, S., Cicchetti, E., Conflitti, G., Broglia, M., Ceccarelli, S., Lazzaro, S., Pagliara, D., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.08.006 · Cited by 68
“Also NK cells, lost in procedure of positive selection of CD34+ cells, exhibit an anti-leukemia effect [24-30], may act as graft-facilitating cells [31], and participate in control of opportunistic infections [32,33].”
BackgroundNK Cell-Based Immunotherapy for Hematological Malignancies
Sivori, S., Meazza, R., Quintarelli, C., Carlomagno, S., Chiesa, M. D., Falco, M., Moretta, L., Locatelli, F., & Pende, D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101702 · Cited by 69
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
Shklovskaya, E., & Rizos, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136741 · Cited by 78
“In the early 21st century, Velardi and colleagues provided the proof-of-principle that NK cells can eliminate cancer cells expressing a KIR inhibitory receptor-mismatched MHC-I allele while avoiding autoimmune side effects, in a setting of haploidentical hematopoietic transplantation for acute leukemias [244].”
BackgroundNatural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy
Zhang, M., Lam, K., & Xu, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1207276 · Cited by 81
“KIR-ligand-mismatch between donors and recipients can even potentially enhance the effectiveness of adoptive NK cell therapy by circumventing inhibitory signals on host cells (22, 23).”
BackgroundLi, J., Giver, C. R., Lu, Y., Hossain, M. S., Akhtari, M., & Waller, E. K. (2009) · Immunotherapy · doi:10.2217/imt.09.32 · Cited by 68
“In the setting of recipients of grafts from haploidentical, partially HLAmatched donors, a median T-cell dose of 3 × 104 cells/kg (range 1 × 104 to 11 × 104 cells/kg) has been used [47,48], although overall risks of GvHD following DLI for HLA-mismatched donor—recipient pairs are much higher at equivalent donor T-cell…”
BackgroundInfluentialAlmalte, Z., Samarani, S., Iannello, A., Débbeche, O., Duval, M., Infante‐Rivard, C., Amre, D. K., Sinnett, D., & Ahmad, A. (2011) · Blood · doi:10.1182/blood-2010-10-313791 · Cited by 67
Immune evasion by oncogenic proteins of acute myeloid leukemia
Elias, S., Yamin, R., Golomb, L., Tsukerman, P., Stanietsky, N., Ben‐Yehuda, D., & Mandelboim, O. (2014) · Blood · doi:10.1182/blood-2013-09-526590 · Cited by 72
Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population
Bontadini, A., Testi, M., Cuccia, M., Martinetti, M., Carcassi, C., Chiesa, A., Cosentini, E., Dametto, E., Frison, S., Iannone, A. M., et al. (2006) · Journal of Translational Medicine · doi:10.1186/1479-5876-4-44 · Cited by 67
“Several studies have associated KIR genes with disease susceptibility, immune responsiveness and events following allogenic transplantation; recent reports have implicated KIRs in affecting the outcome of hematopoietic stem-cell transplantation [11].”
BackgroundStern, L., McGuire, H. M., Avdic, S., Rizzetto, S., Groth, B. F. D. S., Luciani, F., Slobedman, B., & Blyth, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01672 · Cited by 74
Therapeutic Potential of Natural Killer Cells in Gastric Cancer
Du, Y., & Wei, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03095 · Cited by 74
Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
“NK cells, which act as important immune cells, are widely used for transplantation [82,83].”
BackgroundCD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
Acharya, S., Başar, R., Daher, M., Rafei, H., Li, P., Uprety, N., Ensley, E. L., Shanley, M., Kumar, B., Banerjee, P. P., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0096 · Cited by 73
“They engage their targets in an antigen-independent manner and do not cause graft-versus-host disease, making them attractive candidates for off-the-shelf cellular immunotherapy of cancer (8–11).”
BackgroundWhat is natural in natural killer cells?
Vivier, É. (2006) · Immunology Letters · doi:10.1016/j.imlet.2006.07.004 · Cited by 77
Trotta, R., Chen, L., Costinean, S., Josyula, S., Mundy-Bosse, B. L., Ciarlariello, D., Mao, C., Briercheck, E. L., McConnell, K. K., Mishra, A., et al. (2013) · Blood · doi:10.1182/blood-2012-12-467597 · Cited by 66
“Our ability to translate these in vitro observations into successful control of lymphoma growth and improved survival in vivo by adoptively transferring miR-155 tg NK cells into immune-deficient hosts suggests that such adoptive therapy with NK cells engineered to overexpress miR-155 may have a role in diseases such a…”
BackgroundPreynat‐Seauve, O., de Rham, C., Tirefort, D., Ferrari‐Lacraz, S., Krause, K., & Villard, J. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00746.x · Cited by 66
“In haematopoietic stem cell transplantation the role of NK cells in the graftversus-host reaction has been clearly demonstrated in rodents and by human studies [23, 24].”
BackgroundAllogeneic hematopoietic stem cell transplantation in China: where we are and where to go
Lv, M., & Huang, X. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-10 · Cited by 66
“For example, in contrast with ex vivo T cells depletion haplo-HSCT model [34], our finding showed that KIR ligand mismatch is associated with higher aGVHD, a greater relapse rate and inferior survival in our unmanipulated HSCT system [35]; additional results suggested that NK cell allo-reactivity could be covered by m…”
ResultBerghuis, D., Schilham, M. W., Vos, H. I., Santos, S. J., Kloeß, S., Buddingh, E. P., Egeler, R. M., Hogendoorn, P. C. W., & Lankester, A. C. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-8 · Cited by 70
“Moreover, and similar to previous observations in leukemia [10], a potential role for natural killer cell alloreactivity in Ewing sarcoma disease control has been suggested [25].”
BackgroundResultNatural-killer-cell-based treatment in haematopoietic stem-cell transplantation
Passweg, J. R., Koehl, U., Uharek, L., Meyer‐Monard, S., & Tichelli, A. (2006) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2006.06.004 · Cited by 66
“While this translated into a reduction of relapse risk in patients transplanted for an acute myeloid leukemia, no beneficial effect concerning relapse was noted in patients transplanted in chemoresistant relapse (perhaps due to unfavorable effector:target cell ratios) [22] or for adult patients transplanted for B-cell…”
BackgroundNatural Born Killers: NK Cells in Cancer Therapy
Franks, S. E., Wolfson, B., & Hodge, J. W. (2020) · Cancers · doi:10.3390/cancers12082131 · Cited by 75
“It was hypothesized that these toxicities eclipsed the benefit of NK cell alloreactivity [54], and that allogeneic transplantation designed around donor versus recipient NK cell alloreactivity may decrease acute myeloid leukemia (AML) relapse and protect against GVHD [55].”
BackgroundInfluentialSi, C., Gao, J., & Ma, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02045-4 · Cited by 71
“A study by Ruggeri et al. found that KIR-mismatched allogeneic-reactive donor NK cells protected bone marrow transplanted AML patients from AML relapse while avoiding graft-versus-host disease (GVHD) [28, 29].”
BackgroundArpinati, M., Chirumbolo, G., Urbini, B., Perrone, G., Rondelli, D., & Anasetti, C. (2003) · Transplant Immunology · doi:10.1016/s0966-3274(03)00055-8 · Cited by 67
Re, F., Staudacher, C., Zamai, L., Vecchio, V., & Bregni, M. (2006) · Cancer · doi:10.1002/cncr.22002 · Cited by 69
“After transplantation from donors who are KIR ligand-mismatched in the graft-versus-host direction, donor-versus-recipient alloreactive NK cells mediate a graft-versus-leukemia effect and improve engraftment, while not causing graft-versus-host disease.(7,8) Although HLA-matched allogeneic transplantation has recently…”
BackgroundRecognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells
Torelli, G., Peragine, N., Raponi, S., Pagliara, D., Propris, M. D. D., Vitale, A., Bertaina, A., Barberi, W., Moretta, L., Basso, G., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.101931 · Cited by 58
Li, H., Matte-Martone, C. C., Tan, H. S., Venkatesan, S., McNiff, J. M., Demetris, A. J., Jain, D., Lakkis, F. G., Rothstein, D. M., & Shlomchik, W. D. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002965 · Cited by 67
Self-citationInterleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy
Dhupkar, P. M., & Gordon, N. B. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53156-4_2 · Cited by 68
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
Charap, A., Enokida, T., Brody, R., Sfakianos, J. P., Miles, B. A., Bhardwaj, N., & Horowitz, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001523 · Cited by 81
Natural killer cell alloreactivity for leukemia therapy.
Ruggeri, L., Mancusi, A., Perruccio, K., Burchielli, E., Martelli, M., & Velardi, A. (2005) · Journal of immunotherapy · doi:10.1097/01.cji.0000161395.88959.1f · Cited by 70
“Mice that were given alloreactive NK cells as part of the conditioning regimen were able to receive mismatched bone marrow grafts containing up to 30 times the lethal dose of allogeneic T cells without clinical or histologic evidence of GVHD.(49) Finally, alloreactive NK cells did not themselves cause GVHD.”
BackgroundInfluentialSelf-citationNew Developments in Allotransplant Immunology
Barrett, A. J., Rezvani, K., Solomon, S. R., Dickinson, A. M., Wang, X. N., Stark, G. L., Cullup, H., Jarvis, M., Middleton, P. G., & Chao, N. J. A. (2003) · Hematology · doi:10.1182/asheducation-2003.1.350 · Cited by 78
Metadata
- Authors
- Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M. F., & Velardi, A.
- Affiliations
- University of Perugia (IT)
- Yale University (US)
- Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy.
- Ospedale Policlinico San Martino (IT)
- ORCID
- Venue
- Science
- Published
- 2002-03-15
- Volume
- 295
- Issue
- 5562
- Pages
- 2097-2100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2147068163
- Cited by
- 3,380
- References
- 21
- Citations by year
- 2026: 46 · 2025: 92 · 2024: 112 · 2023: 134 · 2022: 157 · 2021: 156 · 2020: 139 · 2019: 155 · 2018: 140 · 2017: 157 · 2016: 152 · 2015: 171 · 2014: 134 · 2013: 162 · 2012: 150
- FWCI
- 63.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL03979)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- natural killer cells, NK cell alloreactivity, allogeneic hematopoietic stem cell transplantation, mismatched transplantation, graft-versus-host disease, graft rejection, leukemia relapse, T cell depletion, conditioning intensity, leukemia
- MeSH terms
- Acute Disease, Animals, Antigen-Presenting Cells, Graft Survival, Graft vs Host Disease, H-2 Antigens, Haplotypes, Histocompatibility Testing, Humans, Killer Cells, Natural, Leukemia, Myeloid, Mice, Inbred Strains, Receptors, Immunologic, Recurrence, T-Lymphocytes, Bone Marrow Transplantation, Mice, SCID, Mice, Inbred NOD, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning, Graft vs Leukemia Effect, Mice, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Receptors, KIR
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.